Fincanna Capital Corp
CNSX:CALI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its Industry Average (1.3), the stock would be worth CA$-0.07 (1 573% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.1 | CA$0.01 |
0%
|
| Industry Average | 1.3 | CA$-0.07 |
-1 573%
|
| Country Average | 2.7 | CA$-0.15 |
-3 011%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
F
|
Fincanna Capital Corp
CNSX:CALI
|
338.1k CAD | -0.1 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 32.7 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 6.8 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.4 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 6.1 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 6.1 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 5.4 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.6 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 1.7 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 6.4 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Fincanna Capital Corp
Glance View
FinCanna Capital Corp. is a royalty company that provides growth capital to rapidly emerging private companies operating in the licensed U.S cannabis industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-12-29. The firm provides growth capital to emerging private companies operating in the licensed United States (U.S) cannabis industry. The company provides capital solution for businesses in the licensed cannabis sector. Its capital solution is provided through royalty financing, which involves providing capital investment for a percentage of the future revenues of an investee. Its subsidiaries include FinCanna Holdings Corp, FCC Holdings Ltd and FCC Ventures, Inc.
